Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | 225Ac-FPI-2059 |
Trade Name | |
Synonyms | [225-Ac]-FPI-2059|Actinium Ac 225 FPI-2059 |
Drug Descriptions |
225Ac-FPI-2059 is a radiotherapy comprising the alpha radiation-emitting radionuclide actinium-225 linked to a molecule that targets NTSR1, which delivers radiation to NSTR1-expressing tumor cells, potentially leading to inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 5045). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C198218 |